Basarır Zehra Ozturk, Arslanca Tufan, Ucar Yesim Ozkaya, Ayhan Sevgi, Ozdal Bülent
Department of Gynecologic Oncology, Ankara City Hospital, Ankara 06800, Turkey.
J Clin Med. 2025 Mar 18;14(6):2050. doi: 10.3390/jcm14062050.
: The aim of this study was to evaluate the serous borderline ovarian tumours (BOTs), the recurrence rates, and the factors affecting recurrence. : A total of 165 patients diagnosed with serous BOT between 2004 and 2019 were included. The patients were evaluated in respect of age, preoperative CA125 levels, FIGO stage, tumour size, stromal micro-invasion, the presence of non-invasive implants, surgical procedures, and lymphadenectomy performed, or all that affects disease-free survival. : Early-stage BOT (stage I-II) was determined in 149 (90.3%) patients. Conservative surgery was performed in 57 (34.5%) patients. The non-invasive implantation was detected in 19 (11.5%) patients, and micro-invasion was determined in 31 (18.8%) patients. The median follow-up was 120 months, and recurrence was observed in 8 (4.8%) patients. The 5-year disease-free survival rate was 95.2%, and the 10-year disease-free survival rate was also 95.2%. Univariate analysis showed that elevated preoperative CA125 levels and the presence of micro-invasion were associated with poor disease-free survival outcomes. In the multivariate analysis, the presence of micro-invasion was the only independent poor prognostic factor (HR: 8.944, 95%CI: 2.060-38.833; p:0.003). : The micro-invasion was the main factor for recurrence in patients with serous BOT.
本研究旨在评估浆液性交界性卵巢肿瘤(BOTs)、复发率及影响复发的因素。
纳入了2004年至2019年间共165例诊断为浆液性BOT的患者。对患者的年龄、术前CA125水平、国际妇产科联盟(FIGO)分期、肿瘤大小、间质微浸润、非侵袭性种植灶的存在情况、手术方式以及是否进行淋巴结清扫术等所有影响无病生存期的因素进行了评估。
149例(90.3%)患者为早期BOT(Ⅰ-Ⅱ期)。57例(34.5%)患者接受了保守手术。19例(11.5%)患者检测到非侵袭性种植,31例(18.8%)患者存在微浸润。中位随访时间为120个月,8例(4.8%)患者出现复发。5年无病生存率为95.2%,10年无病生存率也为95.2%。单因素分析显示,术前CA125水平升高和存在微浸润与无病生存结局不良相关。多因素分析中,微浸润的存在是唯一独立的不良预后因素(风险比:8.944,95%置信区间:2.060-38.833;P:0.003)。
微浸润是浆液性BOT患者复发的主要因素。